David Cowan
Founder and Director, Drug Control Centre, King’s College London
Professor David Cowan is the Director of the King’s College London Drug Control Centre which he co-founded in 1978. He holds a Chair in Pharmaceutical Toxicology and is a Fellow of the Royal Pharmaceutical Society. He was awarded the International Olympic Committee Trophy for Ethics in Sport in 1998. He is also the Head of Department of Forensic Science and Drug Monitoring at King’s College London which runs three very successful M.Sc. programmes in Analytical Science for Industry, Analytical Toxicology and Forensic Science.
Professor Cowan has published extensively in the field of pharmaceutical analysis especially in relation to the detection and quantification of drugs and their metabolites in complex body fluids and detecting drug administration in sport.
The internationally renowned Drug Control Centre is the only WADA accredited laboratory in the UK. Professor Cowan has been selected as the laboratory Director to undertake the drug testing of athletes for the 2012 Olympic Games.
Close
Sigmund Loland
Professor of Sports Philosophy, Norwegian School of Sports Sciences
Sigmund Loland is rector and professor at The Norwegian School of Sport Sciences. He has published extensively on topics such as sport ethics, the epistemology of movement, sport and ecology and sport and performance-enhanching technology. His book Fair Play in Sport (Routledge 2001) is a systematic analysis of normative ideals in current competitive sport and how they can be realised in practice.
Dr. Loland is President-elect of European College of Sport Science and a member of World Antidoping Agency’s Ethical Review Board. He has also a background from alpine skiing both as an athlete and coach.
Close
Matt Lovell
Nutritionist for the England Rugby team
Author of ‘Four Week Fat Loss’ and a muscle building anabolic program ‘Regenerate’.
Matt’s career in sports started as a fitness and karate instructor and then personal trainer. In the mean time he was running his own company in London. After completing a Degree in Political Philosophy (Bristol University) and three years of study at the Institute of Optimum Nutrition, Matt gained specialisation in elite sport, female hormonal health and body composition management. Holding nutritionist positions for Football Clubs, Matt joined the England Rugby (2002) team where he pursued his successful role notably when the team reached the final Rugby World Cup (2007).
Matt currently runs his own elite performance based company, and works with the UK Athletics to prepare London Olympic Games 2012.
Close
Andrew Lynn
Founder, Orthomimetics; CBO, Tigenix
Andrew Lynn received his PhD in Materials Science from the University of Cambridge, UK and went on to found the regenerative medical device company, Orthomimetics Ltd. During his four-year tenure as CEO, Orthomimetics raised £7.5million in venture capital and grant funding, established commercial-scale manufacturing capabilities and brought the company’s flagship product through pilot clinical trials to market. In 2009, Dr Lynn oversaw the successful sale of Orthomimetics to a leading player in the field of regenerative medicine, TiGenix NV, where he is now Chief Business Officer.
His previous experience in the field of orthopaedics has included the management and implementation of product-focused programs involving artificial prostheses for joint replacement and tissue regeneration scaffolds for orthopaedic, neurosurgical, and thoracic applications.
Dr Lynn’s achievements with Orthomimetics have earned him a number of international awards, most notably the 2008 European Academic Enterprise Award (ACES) for Chemistry and Materials and a place in the 2009 MIT Technology Review TR35, its annual list of 35 outstanding men and women under the age of 35 who exemplify the spirit of innovation in business and technology.
Close
David Mountford
Co-founder and COO, MedCell Bioscience
David is a veterinary surgeon with significant management and consultancy experience. He is co-founder of the UCL spin out MedCell and its subsidiary VetCell which has developed an autologous cell therapy for equine athletes and is in the process of translating that technology for the human market. Before founding MedCell/VetCell he held successful European, Middle Eastern, and Asian operational directorships.
He is on the Board of the British Equine Veterinary Association, and the Equine Veterinary Journal and is the veterinary representative to the British Horse Industry Confederation.
Close
Edward Piper
Director of Clinical Development, MedImmune
Dr Ed Piper joined MedImmune Ltd. in January 2009 and is Senior Director for Clinical Development at the UK R&D site based in Cambridge.
Ed qualified in Biochemistry and Medicine at University of London and trained as an NHS General Practitioner, ultimately working as a Partner in a practice in Sevenoaks, Kent.
In 2001 he moved into the Pharmaceutical Industry working for Aventis Pharma and Takeda before joining MedImmune. He has been involved in the global clinical development and commercialisation of both small molecules and biologics for the treatment of cardiovascular disease and diabetes. Currently he works in the MedImmune respiratory franchise on a portfolio of monoclonal antibodies targeted towards areas of unmet medical need including asthma and chronic obstructive pulmonary disease.
Close
Advancing through Biomedical Innovation
Recent developments in sports nutrition and regenerative medicine have significantly enhanced our wellbeing and performance. With the introduction of novel nutritional supplements and next-generation tissue engineering products, we are becoming better, faster and stronger. However, the rapid developments of such technologies also require us to revisit their ethical implications and commercial viability.
The panel will aim to address:
- How will emerging technologies reshape our concept of sports and health?
- Where do we draw the line between advanced medicine and illegal performance enhancing treatments?
- How viable are the current business models in the rapidly evolving sports health industry?
- Is the elite sports market the place to demonstrate the effectiveness of stem cell therapy and tissue engineering?
| 
